Phaseline

Targets › SERPINF2

SERPINF2 (Alpha-2-antiplasmin): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Neurology, Cardiovascular; next expected readout Nov 2026.

Serine protease inhibitor. The major targets of this inhibitor are plasmin and trypsin, but it also inactivates matriptase-3/TMPRSS7 and chymotrypsin. (UniProt, P08697)

Open in Phaseline: the race on SERPINF2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Translational SciencesTS23
Monoclonal antibody to α2-antiplasmin
SERPINF2Phase 2Pulmonary Embolism; Ischemic StrokeNov 2026

Conditions

Pulmonary Embolism (1) Ischemic Stroke (1)

Modalities

small molecule (1)

Companies

Translational Sciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.